Business Description
InnoCare Pharma Ltd
ISIN : KYG4783B1032
Compare
Compare
Traded in other countries / regions
09969.Hong Kong688428.China33C.GermanyINCPF.USA IPO Date
2021-02-08Description
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.44 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.2 | |||||
| Debt-to-EBITDA | -3.8 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 2.74 | |||||
| Beneish M-Score | -0.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 521 | |||||
| 3-Year EBITDA Growth Rate | 10.4 | |||||
| 3-Year EPS without NRI Growth Rate | 6 | |||||
| 3-Year FCF Growth Rate | -5 | |||||
| 3-Year Book Growth Rate | 15.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 33.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 34.85 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.07 | |||||
| 9-Day RSI | 46.08 | |||||
| 14-Day RSI | 47.96 | |||||
| 3-1 Month Momentum % | 38.71 | |||||
| 6-1 Month Momentum % | 63.81 | |||||
| 12-1 Month Momentum % | 8.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.82 | |||||
| Quick Ratio | 3.77 | |||||
| Cash Ratio | 3.57 | |||||
| Days Inventory | 336.75 | |||||
| Days Sales Outstanding | 94.14 | |||||
| Days Payable | 355.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11 | |||||
| Shareholder Yield % | 4.47 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.03 | |||||
| Operating Margin % | -62.29 | |||||
| Net Margin % | -41.62 | |||||
| FCF Margin % | -26.04 | |||||
| ROE % | -5.24 | |||||
| ROA % | -3.79 | |||||
| ROIC % | -19.52 | |||||
| 3-Year ROIIC % | -4.76 | |||||
| ROC (Joel Greenblatt) % | -38.93 | |||||
| ROCE % | -4.73 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 11.73 | |||||
| PB Ratio | 1.59 | |||||
| Price-to-Tangible-Book | 1.55 | |||||
| EV-to-EBIT | -17.73 | |||||
| EV-to-Forward-EBIT | -2.13 | |||||
| EV-to-EBITDA | -18.12 | |||||
| EV-to-Revenue | 7.27 | |||||
| EV-to-Forward-Revenue | 4.39 | |||||
| EV-to-FCF | -29.03 | |||||
| Price-to-GF-Value | 0.78 | |||||
| Price-to-Net-Current-Asset-Value | 2 | |||||
| Price-to-Net-Cash | 2.24 | |||||
| Earnings Yield (Greenblatt) % | -5.63 | |||||
| FCF Yield % | -1.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
InnoCare Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 114.935 | ||
| EPS (TTM) (€) | -0.028 | ||
| Beta | 0.38 | ||
| 3-Year Sharpe Ratio | -0.45 | ||
| 3-Year Sortino Ratio | -0.58 | ||
| Volatility % | 39.03 | ||
| 14-Day RSI | 47.96 | ||
| 14-Day ATR (€) | 0.032145 | ||
| 20-Day SMA (€) | 0.7695 | ||
| 12-1 Month Momentum % | 8.18 | ||
| 52-Week Range (€) | 0.484 - 0.88 | ||
| Shares Outstanding (Mil) | 1,762.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
InnoCare Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
InnoCare Pharma Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
InnoCare Pharma Ltd Frequently Asked Questions
What is InnoCare Pharma Ltd(FRA:33C)'s stock price today?
The current price of FRA:33C is €0.76. The 52 week high of FRA:33C is €0.88 and 52 week low is €0.48.
When is next earnings date of InnoCare Pharma Ltd(FRA:33C)?
The next earnings date of InnoCare Pharma Ltd(FRA:33C) is 2025-03-28 Est..
Does InnoCare Pharma Ltd(FRA:33C) pay dividends? If so, how much?
InnoCare Pharma Ltd(FRA:33C) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers